Alberto Romano

Verified @guest.policlinicogemelli.it

Pediatric Oncologist, Oncologia Pediatrica, Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Alberto Romano


         Download Compact PDF  
https://researchid.co/alberto

RESEARCH INTERESTS

Pediatric oncology, Pediatric Haematology
72

Scopus Publications

Scopus Publications

  • Progressive Sensorineural Hearing Loss Following Cisplatin Chemotherapy: Mechanisms Underlying Cochlear Retention and Long-Term Ototoxicity
    Antonio Ruggiero, Pasqualina Maria Picciotti, Stefano Mastrangelo, Alberto Romano, Dario Talloa, Jacopo Galli, Giorgio Attinà
    Pharmaceuticals, 2026
    Cisplatin-induced ototoxicity is a permanent, bilateral sensorineural hearing loss occurring in up to 80% of treated patients. Its defining and clinically challenging feature is the progressive worsening of auditory function that continues well after chemotherapy has ended, a trajectory that cannot be explained by cumulative dose alone. This article is a comprehensive review of the present research studies on mechanisms that are responsible for this post-treatment progression. The cochlea, unlike other organs, appears to be unable to eliminate platinum (the active divalent metal ion released from cisplatin and responsible for its cytotoxic and ototoxic effects): traces of it can be found in human temporal bone tissue even more than 18 months after last infusion, and bone might serve as a long-term systemic reservoir. Within the inner ear, platinum accumulates preferentially in the stria vascularis, impairing endocochlear potential and outer hair cell function. Retained platinum sustains cascading effects including sustained NOX3-dependent oxidative stress, mitochondrial dysfunction, ongoing genotoxic injury to non-regenerative cells, and the early loss of ribbon synapses that precipitates delayed spiral ganglion neurodegeneration. Pharmacogenetic variability in platinum transport and antioxidant metabolism further modulates individual susceptibility. These findings support lifelong audiological surveillance and provide a basis for designing strategies that can protect hearing without compromising the essential anticancer efficacy of cisplatin therapy.
  • Effects of Clay Therapy on Emotional and Physical Outcomes in Hospitalized Pediatric Cancer Patients: A Prospective Pilot Study
    Antonella Guido, Alberto Romano, Laura Peruzzi, Matilde Tibuzzi, Serena Sannino, Paola Adamo, Daniela Pia Rosaria Chieffo, Antonio Ruggiero
    Cancers, 2026
    Background: Pediatric cancer is a highly stressful and potentially traumatic condition affecting physical health, emotional well-being, developmental trajectories, and family functioning. Hospitalization and intensive treatments often exacerbate emotional distress and symptom burden, negatively impacting quality of life (QoL). Integrating psychosocial and expressive interventions into pediatric oncology care is increasingly recognized as essential. Clay therapy is a multisensory, hands-on creative intervention that may promote emotional regulation, coping, and a sense of agency in hospitalized children. Objectives: This prospective pilot study evaluated the effects of clay therapy on emotional and physical well-being in pediatric oncology patients and explored potential indirect effects on caregivers’ emotional status. Methods: From December 2023 to December 2024, forty hospitalized children with onco-hematological diseases and one parent per patient were enrolled. Each child participated in a one-hour clay therapy workshop led by a professional ceramist. Emotional outcomes were assessed before (T0) and immediately after (T1) the intervention using the Visual Analog Scale (VAS) and the ArtsObs observational scale. Physical symptoms, including pain, fatigue, and nausea, were also evaluated. Results: Following clay therapy, children showed statistically significant improvements across all VAS emotional domains, independent of age and gender. ArtsObs assessments confirmed a significant increase in observed mood, with high levels of relaxation and engagement; female patients demonstrated greater mood improvement than males. Significant reductions in pain, fatigue, and nausea were also observed. Parents exhibited a significant improvement in mood following their child’s participation. Conclusions: These findings suggest that clay therapy is feasible and could be an effective supportive intervention in pediatric oncology, benefiting both emotional and physical well-being. Its integration into multidisciplinary, family-centered care models may enhance QoL during hospitalization and provide holistic support for children with cancer and their families.
  • Diencephalic Syndrome: Clinical Features, Pathophysiology, and Long-Term Outcomes
    Antonio Ruggiero, Palma Maurizi, Alberto Romano, Fernando Fuccillo, Dario Talloa, Stefano Mastrangelo, Giorgio Attinà
    Children, 2026
    Background/Objectives: Diencephalic syndrome (DS) is an uncommon pediatric disorder presenting with severe failure to thrive despite adequate caloric intake and preserved linear growth. First characterized by Russell, this condition predominantly affects infants under 12 months and remains diagnostically challenging. Methods: We performed a comprehensive literature review examining clinical presentation, underlying pathophysiology, associated pathology, diagnostic approaches, and long-term outcomes of DS. Results: DS typically manifests in the first year of life with profound cachexia, normal or increased appetite, preserved height velocity, and characteristic features including hyperactivity, euphorism, and visual pathway involvement. Low-grade gliomas of the hypothalamic–chiasmatic region, particularly pilocytic astrocytomas, represent the predominant underlying pathology. The pathophysiological mechanisms remain incompletely understood but likely involve complex dysregulation of hypothalamic energy homeostasis. While overall survival exceeds 90% at five years, most patients experience significant long-term morbidity including visual impairment, multiple endocrine deficiencies, and hypothalamic obesity. Diagnostic delays averaging 11 months contribute to irreversible complications. Conclusions: Early recognition of DS is essential to prevent permanent visual loss and optimize outcomes. Multidisciplinary management incorporating chemotherapy as first-line treatment for underlying gliomas has improved survival while reducing radiation-associated toxicities. However, survivors face substantial lifelong sequelae requiring comprehensive monitoring and intervention. Future research should focus on elucidating precise pathophysiological mechanisms, developing targeted molecular therapies, and improving management of hypothalamic obesity and other late effects.
  • Concurrent chemoradiotherapy with temozolomide in newly pediatric diffuse intrinsic pontine glioma: clinical outcomes and safety analysis
    Giorgio Attinà, Palma Maurizi, Alberto Romano, Dario Talloa, Tommaso Verdolotti, Paolo Frassanito, Gianpiero Tamburrini, Silvia Chiesa, Stefano Mastrangelo, Antonio Ruggiero
    Translational Pediatrics, 2026
    Background: Diffuse intrinsic pontine glioma (DIPG) is one of the most aggressive pediatric brain tumors, with a median overall survival of less than 12 months despite radiotherapy remaining the current standard of care. This study aimed to evaluate the clinical outcomes and toxicity of concurrent radiotherapy with temozolomide followed by adjuvant therapy in newly diagnosed pediatric DIPG. Methods: /day, days 1-5, every 28 days for ≤13 cycles) was conducted. Primary endpoints included overall survival (OS), progression-free survival (PFS), and treatment-related toxicity. Response assessment utilized standardized neuroimaging criteria at predetermined intervals. Results: Median age was 7 years (range, 3-16 years). H3K27M mutation was detected in 74% of biopsied cases (14/19). Post-radiotherapy imaging showed partial response in 12 patients (50%), stable disease in 9 (38%), and progression in 3 (12%). Median OS was 12.0 months [95% confidence interval (CI): 7.0-14.0]; median PFS was 9.0 months (95% CI: 7.0-12.0). One- and two-year OS rates were 54% and 8%, respectively. Grade 3-4 hematological toxicity occurred in 10 patients (42%): leucopenia (n=4), thrombocytopenia (n=6). No treatment-related deaths occurred. Conclusions: Concurrent chemoradiotherapy achieved encouraging response rates with manageable toxicity profile. However, survival outcomes remain limited, underscoring the need for novel therapeutic approaches targeting specific molecular pathways in this devastating malignancy.
  • Complete response to pembrolizumab in a paediatric patient with Lynch syndrome-associated colorectal cancer: a case report and review of immunotherapy-related bowel obstruction
    Antonio Ruggiero, Fernando Fuccillo, Palma Maurizi, Alberto Romano, Dario Talloa, Stefano Mastrangelo, Michele Basso, Vito Briganti, Maria Cristina Giustiniani, Roberto Persiani, Giorgio Attinà
    Drugs in Context, 2026
    Colorectal cancer (CRC) is extremely rare in paediatrics with aggressive histopathology and advanced presentation. Whilst pembrolizumab has shown efficacy in adult microsatellite instability-high or mismatch repair deficiency CRC, paediatric data remain scarce. A 12-year- old boy with Lynch syndrome-associated CRC developed severe cardiac toxicity after initial chemotherapy. Treatment was switched to off-label pembrolizumab, resulting in a complete response after 24 cycles. Despite good tolerability, the patient developed a delayed bowel stricture at the tumour site. After surgery, there was no pathological evidence of residual adenocarcinoma. This case demonstrates the potential of pembrolizumab in paediatric CRC, highlighting the importance of molecular-guided rather than age-restricted therapy selection.
  • Adolescent Renal Tumours: Diagnostic and Therapeutic Challenges in a Transitional Age Group—A Multidisciplinary Case Report Series from a Single Center
    Antonio Ruggiero, Fernando Fuccillo, Valerio Di Paola, Alberto Romano, Palma Maurizi, Dario Talloa, Nazario Foschi, Pierluigi Russo, Marco Racioppi, Stefano Mastrangelo, Giorgio Attinà
    Oncology Research, 2026
    Background: The management of renal neoplasms in adolescent patients poses unique clinical challenges due to their transitional position between paediatric and adult populations. This age group exhibits marked heterogeneity in tumour histology, ranging from entities commonly observed in paediatric oncology to tumours typical of adult age, as well as rare histological subtypes that exceptionally affect the kidney. Given the substantial differences in clinical protocols between paediatric and adult populations, rigorous multidisciplinary evaluation is essential to determine optimal diagnostic and therapeutic strategies for adolescent patients. Case Description: We present four cases from our tertiary referral centre that illustrate the variability in radiological and histopathological presentations and clinical outcomes in this population, underscoring the critical importance of a multidisciplinary approach. Case 1 demonstrates the typical management of Wilms' tumour in an older paediatric patient. Case 2 exemplifies the diagnostic challenge of distinguishing between Wilms' tumour and renal cell carcinoma at the upper end of the adolescent spectrum. Case 3 revealed the unexpected diagnosis of renal Ewing sarcoma in a 13-year-old female. Case 4 highlights the potential for severe perioperative complications, including life-threatening thromboembolic events, in a patient with Wilms' tumour. Conclusions: The variability in tumour types, biological behaviour, and potential for severe complications underscores the necessity of comprehensive multidisciplinary management in specialized hospital settings. An integrated approach ensures accurate diagnosis, individualized treatment planning, and effective management of complications, ultimately optimizing outcomes for adolescent patients with renal neoplasms.
  • The state of targeted therapeutic pharmacological approaches in pediatric neurosurgery: report from the European Society for Pediatric Neurosurgery (ESPN) Consensus Conference 2024
    P. Frassanito, U. W. Thomale, M. Obersnel, A. Romano, P. Leblond, F. Knerlich-Lukoschus, B. J. Due-Tønnessen, D. Thompson, F. Di Rocco, and
    Child S Nervous System, 2025
    Objective The development of novel targeted therapies is opening new perspectives in the treatment of pediatric brain tumors. Their precise role in therapeutic protocols still needs still to be defined. Thus, these novel pharmacological approaches in pediatric neurosurgery were the topic of the European Society for Pediatric Neurosurgery (ESPN) Consensus Conference held in Lyon (France) in January 25–27, 2024. Method The paper reviews the current knowledge about targeted therapy as well as the current literature published on the topic. The conference aimed for an interdisciplinary consensus debate among pediatric oncologists and pediatric neurosurgeons on the following questions. Question 1: What is the current role for targeted therapies as neoadjuvant treatments before pediatric brain tumor removal? Question 2: What are the benefits, cost/efficiency, and long-term side effects of targeted therapies in the treatment of pediatric brain tumors? Question 3: Based on contemporary data, at which stage and in which pathologies do targeted therapies play a significant role? Results Ninety-two participants answered consensus polls on the state of the art of targeted therapies, the ethical issues related to their use, and the evolving change in the role of pediatric neurosurgeons. The neoadjuvant role of targeted therapies is difficult to define as there are many different entities to consider. Despite the recently reported potential benefits, questions regarding the use of targeted therapies are manifold, in particular regarding sustainable benefits and long-term side effects. Additionally, challenging cost issues is a limiting factor for the broader availability of these drugs. Studies have demonstrated superiority of targeted therapy compared to chemotherapy both in randomized trials and compared to historical cohorts in the management of a subset of low-grade gliomas. The same drug combinations, BRAFi and MEKi, may be effective in HGG that have relapsed, progressed, or failed to respond to first-line therapy. Similar conclusions on efficacy may be drawn for mTORi in TSC and selumetinib in plexiform neurofibromas. For other tumors, the picture is still obscure due to the lack of data or even the lack of suitable targets. In conclusion, targeted treatment may not always be the best option even when a target has been identified. Safe surgery remains to be a favorable option in the majority of cases. Conclusion The constantly evolving drug technology and the absence of long-term safety and efficacy studies made it difficult to reach a consensus on the predefined questions. However, a report of the conference is summarizing the present debate and it might serve as a guideline for future perspectives and ongoing research.
  • The influence of tumor location on the onset of endocrine deficits in pediatric brain tumor survivors
    Giorgio Attinà, Alberto Romano, Palma Maurizi, Tommaso Verdolotti, Stefano Mastrangelo, Antonio Ruggiero
    Translational Cancer Research, 2025
    Background: Pediatric central nervous system (CNS) tumors are the second most common malignancy in children and are associated with significant long-term morbidity despite advancements in therapy. Endocrine dysfunction is one of the most frequent and impactful late sequelae, requiring timely detection and management. This study aimed to investigate the timing and risk factors associated with endocrine dysfunction in pediatric brain tumor survivors and to propose optimized follow-up protocols. Methods: A cohort of 33 pediatric patients with brain tumors, excluding craniopharyngiomas, pituitary adenomas, and germ cell tumors, treated at the Pediatric Oncology Unit of Fondazione Policlinico Universitario "Agostino Gemelli" IRCCS in Rome (2005-2015), was retrospectively analyzed. Endocrine dysfunction was assessed through clinical and laboratory evaluations, with a median follow-up of 114.1 months. Results: Endocrine dysfunction was identified in a high percentage of patients, with hypothyroidism and panhypopituitarism being the most common. Age at diagnosis and treatment influenced the appearance and the timing of dysfunction. Hypothalamic and suprasellar tumors were associated with early onset, while tumors in posterior cranial fossa exhibited delayed onset. Conclusions: Tumor location and patient age are critical determinants of the timing of endocrine dysfunction in pediatric brain tumor survivors. We propose a stratified follow-up based on tumor location, with immediate evaluation for hypothalamic and supratentorial tumors and periodic assessments for other regions. These tailored recommendations aim to ensure timely detection and management of endocrine complications, improving outcomes and quality of life. Future research with larger cohorts is needed to validate and refine these findings.
  • Metronomic Chemotherapy: An Alternative Strategy in Cancer Treatment Based on Continuous Low-Dose Administration
    Giorgio Attina, Stefano Mastrangelo, Alberto Romano, Dario Talloa, Palma Maurizi, Antonio Ruggiero
    Biomedical and Pharmacology Journal, 2025
    Traditionally, cancer treatment relied on the maximum tolerated dose (MTD) approach, in which chemotherapeutic agents are given at the highest dose that patients can tolerate, with scheduled breaks to allow for recovery. However, this method has notable drawbacks, including significant toxicity, tumor regrowth during drug-free intervals, and the development of resistance. Metronomic chemotherapy offers an innovative alternative, characterized by continuous low-dose administration without treatment interruptions. This approach primarily targets the tumor microenvironment, including tumor vasculature and cancer stem cells, while also affecting the immune system. By maintaining a steady level of drug exposure, metronomic therapy prevents the recovery of tumor endothelial cells and enhances immune surveillance, leading to prolonged disease stabilization and potentially improved long-term outcomes. Due to its reduced toxicity, cost-effectiveness, and suitability for oral administration, metronomic chemotherapy is especially beneficial for long-term maintenance therapy for the elderly, or frail patients. This review explores the mechanisms, clinical advantages, and challenges of metronomic chemotherapy, as well as its potential for integration with other treatment modalities to improve patient outcomes. Additional research is needed to optimize drug dosing, identify biomarkers for treatment response, and conduct large-scale clinical trials comparing metronomic approaches with standard chemotherapy regimens.
  • Platinum-Induced Ototoxicity in Pediatric Cancer Patients: A Comprehensive Approach to Monitoring Strategies, Management Interventions, and Future Directions
    Antonio Ruggiero, Alberto Romano, Palma Maurizi, Dario Talloa, Fernando Fuccillo, et al.
    Children, 2025
    Platinum-induced ototoxicity constitutes a significant adverse effect in pediatric oncology, frequently resulting in permanent hearing impairment with profound implications for quality of life, language acquisition, and scholastic performance. This comprehensive review critically evaluates contemporary ototoxicity monitoring practices across various pediatric oncology settings, analyzes current guideline recommendations, and formulates strategies for implementing standardized surveillance protocols. Through examination of recent literature-encompassing retrospective cohort investigations, international consensus recommendations, and functional outcome assessments-we present an integrated analysis of challenges and opportunities in managing chemotherapy-associated hearing loss among childhood cancer survivors. Our findings demonstrate marked heterogeneity in monitoring methodologies, substantial implementation obstacles, and considerable impact on survivors' functional status across multiple domains. Particularly concerning is the persistent absence of an evidence-based consensus regarding the appropriate duration of audiological surveillance for this vulnerable population. We propose a structured framework for comprehensive ototoxicity management emphasizing prompt detection, standardized assessment techniques, and integrated long-term follow-up care to minimize the developmental consequences of platinum-induced hearing impairment. This approach addresses critical gaps in current practice while acknowledging resource limitations across diverse healthcare environments.
  • Medulloblastoma in Adolescents and Young Adults (AYA): Bridging Pediatric Paradigms and Adult Oncology Practice
    Antonio Ruggiero, Giorgio Attinà, Dario Talloa, Stefano Mastrangelo, Alberto Romano, Palma Maurizi, Silvia Chiesa, Gianpiero Tamburrini, Alessandro Olivi, Alessio Albanese
    Journal of Clinical Medicine, 2025
  • Burnout in Pediatric Oncology: Team Building and Clay Therapy as a Strategy to Improve Emotional Climate and Group Dynamics in a Nursing Staff
    Antonella Guido, Laura Peruzzi, Matilde Tibuzzi, Serena Sannino, Lucia Dario, Giulia Petruccini, Caterina Stella, Anna Maria Viteritti, Antonella Becciu, Francesca Bianchini, Deborah Cucculelli, Carmela Di Lauro, Ivana Paglialonga, Sabina Pianezzi, Roberta Pistilli, Sabrina Russo, Paola Adamo, Daniela Pia Rosaria Chieffo, Dario Talloa, Alberto Romano, Antonio Ruggiero
    Cancers, 2025
  • Platinum-induced ototoxicity and hearing impairment in children and adolescents
    Alberto Romano, Giorgio Attinà, Palma Maurizi, Dario Talloa, Stefano Mastrangelo, Antonio Ruggiero
    Drugs in Context, 2025
  • Outcomes and Toxicity of Adult Medulloblastoma Treated with Pediatric Multimodal Protocols: A Single-Institution Experience
    Antonio Ruggiero, Dario Talloa, Alberto Romano, Giorgio Attinà, Stefano Mastrangelo, Palma Maurizi, Tommaso Verdolotti, Gianpiero Tamburrini, Silvia Chiesa, Rina di Bonaventura, Pier Paolo Mattogno, Alessandro Olivi, Alessio Albanese
    Oncology Research, 2025
  • Nutritional Challenges in Paediatric Oncology: Screening and Managing Malnutrition and Sarcopenia
    Stefano Mastrangelo, Alberto Romano, Palma Maurizi, Daniela Rizzo, Giorgio Attinà, Antonio Ruggiero
    Biomedical and Pharmacology Journal, 2024
  • Anthropometric parameters as a tool for the prediction of metabolic and cardiovascular risk in childhood brain tumor survivors
    Alberto Romano, Mariapia Masino, Serena Rivetti, Stefano Mastrangelo, Giorgio Attinà, Palma Maurizi, Antonio Ruggiero
    Diabetology and Metabolic Syndrome, 2024
  • Neonatal outcomes and follow-up of children born to women with pregnancy-associated cancer: a prospective observational study
    Michele Antonio Capozza, Alberto Romano, Stefano Mastrangelo, Giorgio Attinà, Palma Maurizi, Simonetta Costa, Giovanni Vento, Giovanni Scambia, Antonio Ruggiero
    BMC Pregnancy and Childbirth, 2024
  • Bioelectrical Impedance Analysis of Body Composition in Male Childhood Brain Tumor Survivors
    A. Romano, F. Sollazzo, Fabio Corbo, G. Attina’, S. Mastrangelo, Simona Cordaro, G. Modica, Isabella Carlotta Zovatto, Riccardo Monti, M. Bianco, P. Maurizi, Vincenzo Palmieri, Antonio Ruggiero
    Diseases, 2024
  • Central nervous system pediatric multi-disciplinary tumor board: a single center experience
    Rosellina Russo, Tommaso Verdolotti, Alessandro Perna, Luigi Ruscelli, Rosa D’Abronzo, Alberto Romano, Giuseppe Ferrara, Davide Parisi, Amato Infante, Silvia Chiesa, Luca Massimi, Gianpiero Tamburrini, Antonio Ruggiero, Marco Gessi, Matia Martucci, Simona Gaudino
    BMC Cancer, 2024
  • Pathogenic G6PD variants: Different clinical pictures arise from different missense mutations in the same codon
    Simonetta Costa, Angelo Minucci, Amit Kumawat, Maria De Bonis, Giorgia Prontera, Mariannita Gelsomino, Milena Tana, Eloisa Tiberi, Alberto Romano, Antonio Ruggiero, Stefano Mastrangelo, Giuseppe Palumbo, Valentina Giorgio, Maria Elisabetta Onori, Martino Bolognesi, Carlo Camilloni, Lucio Luzzatto, Giovanni Vento
    British Journal of Haematology, 2024
  • Characteristics and Management of Children with Appendiceal Neuroendocrine Neoplasms: A Single-Center Study
    Stefano Mastrangelo, Giorgio Attinà, Guido Rindi, Alberto Romano, Palma Maurizi, Antonio Ruggiero
    Cancers, 2024
  • The Role of the Cerebellum in Advanced Cognitive Processes in Children
    Stefano Mastrangelo, Laura Peruzzi, Antonella Guido, Laura Iuvone, Giorgio Attinà, Alberto Romano, Palma Maurizi, Daniela Pia Rosaria Chieffo, Antonio Ruggiero
    Biomedicines, 2024
  • Unveiling the genetic landscape of suspected congenital dyserythropoietic anemia type I: A retrospective cohort study of 36 patients
    Roberta Marra, Antonella Nostroso, Barbara Eleni Rosato, Federica Maria Esposito, Vanessa D'Onofrio, Anthony Iscaro, Antonella Gambale, Barbara Bruschi, Paola Coccia, Antonella Poloni, Sule Unal, Alberto Romano, Achille Iolascon, Immacolata Andolfo, Roberta Russo
    American Journal of Hematology, 2024
  • Psychological Experiences of Parents of Pediatric Cancer Patients during and after COVID-19 Pandemic
    Antonella Guido, Elisa Marconi, Laura Peruzzi, Nicola Dinapoli, Gianpiero Tamburrini, Giorgio Attinà, Alberto Romano, Palma Maurizi, Stefano Mastrangelo, Silvia Chiesa, Maria Antonietta Gambacorta, Antonio Ruggiero, Daniela Pia Rosaria Chieffo
    Cancers, 2024
  • Metaiodobenzylguanidine: An essential imaging diagnostic tool for the diagnosis and treatment of neuroblastoma
    Current Topics in Pharmacology, 2024
  • Childhood Obesity and Metabolic Syndrome: A Review
    Giorgio Attina, Stefano Mastrangelo, Palma Maurizi, Alberto Romano, Antonio Ruggiero
    Biomedical and Pharmacology Journal, 2024
  • Evaluation of Metabolic and Cardiovascular Risk Measured by Laboratory Biomarkers and Cardiopulmonary Exercise Test in Children and Adolescents Recovered from Brain Tumors: The CARMEP Study
    Alberto Romano, Fabrizio Sollazzo, Serena Rivetti, Lorenzo Morra, Tiziana Servidei, Donatella Lucchetti, Giorgio Attinà, Palma Maurizi, Stefano Mastrangelo, Isabella Carlotta Zovatto, Riccardo Monti, Massimiliano Bianco, Vincenzo Palmieri, Antonio Ruggiero
    Cancers, 2024
  • European expert recommendations on clinical investigation and evaluation of high-risk medical devices for children
    Kathrin Guerlich, Bernadeta Patro‐Golab, Alex Barnacle, Ulrich Baumann, Andreas Eicken, Alan G. Fraser, Dariusz Gruszfeld, Nikolaus A. Haas, Anneliene H. Jonker, Michael Kammermeier, Damien Kenny, Sanja Kolaček, Risto Lapatto, Ian Maconochie, Silke Mader, Gearóid McGauran, Tom Melvin, Oliver Muensterer, Paul Piscoi, Alberto Romano, Amulya K. Saxena, Dominik T. Schneider, Mark A. Turner, Johan Vande Walle, Berthold Koletzko, and
    Acta Paediatrica International Journal of Paediatrics, 2023
  • Timing and chemotherapy association for 131-I-MIBG treatment in high-risk neuroblastoma
    Stefano Mastrangelo, Alberto Romano, Giorgio Attinà, Palma Maurizi, Antonio Ruggiero
    Biochemical Pharmacology, 2023
  • Aminoglycosides-Related Ototoxicity: Mechanisms, Risk Factors, and Prevention in Pediatric Patients
    Serena Rivetti, Alberto Romano, Stefano Mastrangelo, Giorgio Attinà, Palma Maurizi, Antonio Ruggiero
    Pharmaceuticals, 2023
  • Successful stem cell collection for atypical teratoid rhabdoid tumor in an extremely low-body weight child: A case report
    Rossana Putzulu, Alberto Romano, Aldo Mancino, Andrea Corbingi, Giuseppina Massini, Stefano Mastrangelo, Silvia Maria Pulitanò, Marco Piastra, Mauro Pittiruti, Antonio Ruggiero, Nicola Piccirillo
    Journal of Clinical Apheresis, 2023
  • Pregnancy-associated Cancer and Chemotherapy during Pregnancy
    Alberto Romano, Stefano Mastrangelo, Giorgio Attina, Palma Maurizi, Antonio Ruggiero
    Biomedical and Pharmacology Journal, 2023
  • Left Ventricular-Arterial Coupling and Vascular Function in Childhood Cancer Survivors Exposed to Anthracycline Chemotherapy
    Massimiliano Camilli, Lisa Birritella, Angelica Bibiana Delogu, Priscilla Lamendola, Antonio De Vita, Veronica Melita, Alberto Romano, Antonio Ruggiero, Giorgio Attinà, Gaetano Antonio Lanza, Massimo Massetti, Filippo Crea, Antonella Lombardo
    Reviews in Cardiovascular Medicine, 2023
  • Early and Long-Term Ototoxicity Noted in Children Due to Platinum Compounds: Prevalence and Risk Factors
    Alberto Romano, Serena Rivetti, Francesca Brigato, Stefano Mastrangelo, Giorgio Attinà, Palma Maurizi, Jacopo Galli, Anna Rita Fetoni, Antonio Ruggiero
    Biomedicines, 2023
  • Bisphosphonates: From Pharmacology to Treatment
    Antonio Ruggiero, Silvia Triarico, Alberto Romano, Palma Maurizi, Giorgio Attina, Stefano Mastrangelo
    Biomedical and Pharmacology Journal, 2023
  • Pediatric low-grade glioma and neurofibromatosis type 1: A single-institution experience
    Antonio Ruggiero, Giorgio Attinà, Anastasia Campanelli, Palma Maurizi, Silvia Triarico, Alberto Romano, Luca Massimi, Gianpiero Tamburrini, Tommaso Verdolotti, Stefano Mastrangelo
    Journal of Cancer Research and Therapeutics, 2023
  • Induction Regimen in High-Risk Neuroblastoma: A Pilot Study of Highly Effective Continuous Exposure of Tumor Cells to Radio-Chemotherapy Sequence for 1 Month. The Critical Role of Iodine-131-Metaiodobenzylguanidine
    Stefano Mastrangelo, Giorgio Attinà, Luca Zagaria, Alberto Romano, Antonio Ruggiero
    Cancers, 2022
  • Serum Biomarkers for the Detection of Cardiac Dysfunction in Childhood Cancers Receiving Anthracycline-Based Treatment
    Giorgio Attina’, Silvia Triarico, Alberto Romano, Palma Maurizi, Stefano Mastrangelo, Antonio Ruggiero
    Biomedical and Pharmacology Journal, 2022
  • BRAF and MEK Targeted Therapies in Pediatric Central Nervous System Tumors
    Dario Talloa, Silvia Triarico, Pierpaolo Agresti, Stefano Mastrangelo, Giorgio Attinà, Alberto Romano, Palma Maurizi, Antonio Ruggiero
    Cancers, 2022
  • Transplacental Passage and Fetal Effects of Antineoplastic Treatment during Pregnancy
    Silvia Triarico, Serena Rivetti, Michele Antonio Capozza, Alberto Romano, Palma Maurizi, Stefano Mastrangelo, Giorgio Attinà, Antonio Ruggiero
    Cancers, 2022
  • Biomarkers Predictive of Metabolic Syndrome and Cardiovascular Disease in Childhood Cancer Survivors
    Alberto Romano, Ester Del Vescovo, Serena Rivetti, Silvia Triarico, Giorgio Attinà, Stefano Mastrangelo, Palma Maurizi, Antonio Ruggiero
    Journal of Personalized Medicine, 2022
  • Growth hormone replacement therapy in pediatric brain tumor survivors
    Giorgio Sodero, Pierpaolo Agresti, Silvia Triarico, Alberto Romano, Stefano Mastrangelo, Giorgio Attinà, Palma Maurizi, Clelia Cipolla, Antonio Ruggiero
    Minerva Pediatrics, 2022
  • Oral Microbiota during Childhood and Its Role in Chemotherapy-Induced Oral Mucositis in Children with Cancer
    Silvia Triarico, Pierpaolo Agresti, Emanuele Rinninella, Maria Cristina Mele, Alberto Romano, Giorgio Attinà, Palma Maurizi, Stefano Mastrangelo, Antonio Ruggiero
    Pathogens, 2022
  • Nutritional status in the pediatric oncology patients
    Silvia Triarico, Emanuele Rinninella, Giorgio Attinà, Alberto Romano, Palma Maurizi, Stefano Mastrangelo, Antonio Ruggiero
    Frontiers in Bioscience Elite, 2022
  • Hypersensitivity reactions to platinum drugs
    Current Topics in Pharmacology, 2022
  • The DNA-topoisomerase Inhibitors in Cancer Therapy
    Stefano Mastrangelo, Giorgio Attina, Silvia Triarico, Alberto Romano, Palma Maurizi, Antonio Ruggiero
    Biomedical and Pharmacology Journal, 2022
  • Hematological disorders in children with Down syndrome
    Silvia Triarico, Giovanna Trombatore, Michele Antonio Capozza, Alberto Romano, Stefano Mastrangelo, Giorgio Attinà, Palma Maurizi, Antonio Ruggiero
    Expert Review of Hematology, 2022
  • Clinical Impact of Nutritional Status and Sarcopenia in Pediatric Patients with Bone and Soft Tissue Sarcomas: A Pilot Retrospective Study (SarcoPed)
    Alberto Romano, Silvia Triarico, Emanuele Rinninella, Luigi Natale, Maria Gabriella Brizi, Marco Cintoni, Pauline Raoul, Palma Maurizi, Giorgio Attinà, Stefano Mastrangelo, Antonio Gasbarrini, Maria Cristina Mele, Antonio Ruggiero
    Nutrients, 2022
  • Mechanisms, characteristics and treatment of neuropathic pain and peripheral neuropathy associated with dinutuximab in neuroblastoma patients
    Stefano Mastrangelo, Serena Rivetti, Silvia Triarico, Alberto Romano, Giorgio Attinà, Palma Maurizi, Antonio Ruggiero
    International Journal of Molecular Sciences, 2021
  • Role of partial splenectomy in hematologic childhood disorders
    Giorgio Attina’, Silvia Triarico, Alberto Romano, Palma Maurizi, Stefano Mastrangelo, Antonio Ruggiero
    Pathogens, 2021
  • Cardiac Surveillance for Early Detection of Late Subclinical Cardiac Dysfunction in Childhood Cancer Survivors After Anthracycline Therapy
    Rosaria Sofia, Veronica Melita, Antonio De Vita, Antonio Ruggiero, Alberto Romano, Giorgio Attinà, Lisa Birritella, Priscilla Lamendola, Antonella Lombardo, Gaetano Antonio Lanza, Angelica Bibiana Delogu
    Frontiers in Oncology, 2021
  • Vincristine-induced peripheral neuropathy (Vipn) in pediatric tumors: Mechanisms, risk factors, strategies of prevention and treatment
    Silvia Triarico, Alberto Romano, Giorgio Attinà, Michele Antonio Capozza, Palma Maurizi, Stefano Mastrangelo, Antonio Ruggiero
    International Journal of Molecular Sciences, 2021
  • Management of Oral Mucositis in Children With Malignant Solid Tumors
    Giorgio Attinà, Alberto Romano, Palma Maurizi, Sara D’Amuri, Stefano Mastrangelo, Michele Antonio Capozza, Silvia Triarico, Antonio Ruggiero
    Frontiers in Oncology, 2021
  • Covid-19 and children with cancer: are they at increased risk of infection?
    Antonio Ruggiero, Alberto Romano, Giorgio Attinà
    Pediatric Research, 2021
  • Doxorubicin pharmacokinetics in children with cancer
    Current Topics in Pharmacology, 2021
  • Transdermal buprenorphine for pain management in children
    Giorgio Attinà, Alberto Romano, Silvia Triarico, Stefano Mastrangelo, Palma Maurizi, Antonio Ruggiero
    Drugs in Context, 2021
  • Cisplatin-induced nephrotoxicity in children: what is the best protective strategy?
    Antonio Ruggiero, Anna Ariano, Silvia Triarico, Michele Antonio Capozza, Alberto Romano, Palma Maurizi, Stefano Mastrangelo, Giorgio Attinà
    Journal of Oncology Pharmacy Practice, 2021
  • Melanocytic nevi in RASopathies: insights on dermatological diagnostic handles
    C. Leoni, C. Guerriero, R. Onesimo, V. Coco, C. Di Ruscio, A. Acampora, I. Esposito, A. Romano, M. Tartaglia, M. Genuardi, G. Zampino
    Journal of the European Academy of Dermatology and Venereology, 2021
  • Managing children with brain tumors during the COVID-19 era: Don't stop the care!
    Michele Antonio Capozza, Silvia Triarico, Giorgio Attinà, Alberto Romano, Stefano Mastrangelo, Palma Maurizi, Paolo Frassanito, Federico Bianchi, Tommaso Verdolotti, Marco Gessi, Mario Balducci, Luca Massimi, Gianpiero Tamburrini, Antonio Ruggiero
    Computational and Structural Biotechnology Journal, 2021
  • Management of children with optic gliomas and neurofibromatosis type 1
    Giorgio Attina, Palma Maurizi, Silvia Triarico, Michele Antonio Capozza, Alberto Romano, Stefano Mastrangelo, Antonio Ruggiero
    Biomedical and Pharmacology Journal, 2020
  • Temozolomide and oral etoposide in children with recurrent malignant brain tumors
    Antonio Ruggiero, Anna Ariano, Silvia Triarico, Michele Antonio Capozza, Alberto Romano, Palma Maurizi, Stefano Mastrangelo, Giorgio Attinà
    Drugs in Context, 2020
  • Assessment and management of platinum-related ototoxicity in children treated for cancer
    Alberto Romano, Michele Antonio Capozza, Stefano Mastrangelo, Palma Maurizi, Silvia Triarico, Rolando Rolesi, Giorgio Attinà, Anna Rita Fetoni, Antonio Ruggiero
    Cancers, 2020
  • Facing the COVID-19 outbreak in children with cancer
    Antonio Ruggiero, Alberto Romano, Giorgio Attinà
    Drugs in Context, 2020
  • Carboplatin-related toxicity in children with cancer
    Current Topics in Pharmacology, 2020
  • Pharmacology and scheduling of Temozolomide
    Current Topics in Pharmacology, 2020
  • Autoimmune phenomena involving the pituitary gland in children: New developing data about diagnosis and treatment
    Alberto Romano, Donato Rigante, Clelia Cipolla
    Autoimmunity Reviews, 2019
  • New high intensity fibreoptic phototherapy devices in healthy newborns: A single pad wrapped around the neonate body in comparison with a double pad device
    R. Luciano, G. Mancini, F. Cota, A. Romano, V. Purcaro, F. Lerro, M. Corsello, G. Vento
    Italian Journal of Pediatrics, 2019
  • Diagnostic criteria for acute food protein-induced enterocolitis syndrome. Is the work in progress?
    S. Miceli Sopo, G. Bersani, C. Fantacci, A. Romano, S. Monaco
    Allergologia Et Immunopathologia, 2018
  • Is food protein induced enterocolitis syndrome only a non IgE-mediated food allergy?
    S. Miceli Sopo, C. Fantacci, G. Bersani, A. Romano, L. Liotti, S. Monaco
    Allergologia Et Immunopathologia, 2018
  • Loss of tolerance for fishes previously tolerated in children with fish food protein induced enterocolitis syndrome
    S. Miceli Sopo, C. Fantacci, G. Bersani, A. Romano, S. Monaco
    Allergologia Et Immunopathologia, 2018
  • Proposal for management of the infant with suspected food protein-induced allergic proctocolitis
    Stefano Miceli Sopo, Serena Monaco, Giulia Bersani, Alberto Romano, Claudia Fantacci
    Pediatric Allergy and Immunology, 2018
  • Endothelial dysfunction and cardiovascular risk factors in childhood acute lymphoblastic leukemia survivors
    Paola Giordano, Paola Muggeo, Maurizio Delvecchio, Santa Carbonara, Alberto Romano, Maria Altomare, Gabriella Ricci, Federica Valente, Annapaola Zito, Pietro Scicchitano, Luciano Cavallo, Marco Matteo Ciccone, Nicola Santoro, Maria Felicia Faienza
    International Journal of Cardiology, 2017